mHealth for Breast Cancer Survivors With Insomnia
Testing mHealth Delivery of Cognitive Behavioral Therapy for Insomnia to Breast Cancer Survivors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Hannah Arem, PhD
- Phone Number: 202-893-2430
- Email: hannah.arem@medstar.net
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- MedStar Washington Hospital Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Willingness to maintain a consistent dosing pattern if currently taking sleep medications or using cannabis for sleep
- Females; Age 18+
- Self-reported or documented diagnosis of breast cancer stage I-III or stage IV ECOG 0-1
- Completed curative treatment (surgery, radiation, chemotherapy) > 3 months prior to enrollment [ongoing adjuvant therapy permitted]
- Has not undergone other behavioral sleep treatment within the prior 12 months
- Score greater than or equal to 8 on the Insomnia Severity Index
- Able to understand and speak English
Exclusion Criteria:
- Diagnosed, untreated obstructive sleep apnea syndrome, narcolepsy, restless leg syndrome, periodic limb movement disorder, delayed sleep phase syndrome, central apnea
- Bi-polar disorder, schizophrenia, initiation of psychological treatment within three months, alcohol or drug abuse in the prior year (Alcohol >2 drinks/day or consuming 5+ drinks in a single day in the prior month). (Moderate ADHD, depression and anxiety will not be exclusion criteria.)
- Shift-work in the prior three months or anticipated during the study time
- Planned regular travel out of time zone (>1 hour) during the study period.
- Currently or planning to become pregnant during the study period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Voice-Activated Smart Speaker Program
Faster Asleep
|
Participants will receive a smart speaker device with a pre-loaded Faster Asleep program.
Participants will be asked to engage with the program daily, either using the voice-activated speakers or an accompanying smart-phone app.
The study duration is six-weeks and is completed individually using fully automated interaction to deliver components of cognitive behavioral therapy for insomnia.
|
|
Active Comparator: Website
Faster Asleep Website
|
Controls will have access to a website with information about CBT-I and breast cancer survivorship and will be told to engage with the website as desired.
The content will be drawn from the education script that is programmed into the phone app accompanying the smart speaker program.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Insomnia Symptoms
Time Frame: 6 weeks
|
Data will be collected on the Insomnia Severity Index (ISI) total score pre- and post-intervention as our primary outcome.
The ISI is a seven-item questionnaire with response categories from 0-4 (total score 0-28) asking about sleep patterns and specifically characterizing insomnia over the two weeks prior.
The ISI defines 'no clinically significant' insomnia as a score of 0-7, 'sub-threshold' insomnia as a score of 8-14, 'moderate severity clinical' insomnia' a scores of 15-21, and 'severe clinical' insomnia as a score of 22-28.
Clinically relevant target for success is to achieve sub-threshold or better scores (≤14) among >80% of the intervention participants
|
6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Six Week Change in Sleep Efficiency
Time Frame: 6 weeks
|
Sleep efficiency is calculated by the total time sleeping over the total time in bed.
|
6 weeks
|
|
Six Week Change in Wake After Sleep Onset
Time Frame: 6 weeks
|
Amount of time awake during the night
|
6 weeks
|
|
Six Week Change in Sleep Onset Latency
Time Frame: 6 weeks
|
Time to fall asleep
|
6 weeks
|
|
Six Week Change in Total Sleep Time
Time Frame: 6 weeks
|
Total time asleep
|
6 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
System Usability Scale
Time Frame: 6 weeks
|
A 10-item scale on general usability of technology.
This provides a score of 0-100, with above 68 indicating better than average usability, where higher is better.
This is a normalized score and not a percentage.
|
6 weeks
|
|
End of Study Self-reported Sleep Quality
Time Frame: 6 weeks
|
5-item Likert scale from Very Poor (5) to Very Good (1).
|
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Hannah Arem, PhD, Medstar Health Research Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 4298
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.